ACE2 and COVID-19: Interestingly, the overexpression of eicosanoids we found associated in this study to cells with high ACE2 levels regardless of their SARS-CoV-2 infection, were found to be diminished in recovered COVID-19 patients68, further underlining the virus capability to exacerbate pre-existing morbidity conditions.